Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vista Medical Technologies, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Files with SEC for a 7 mil.-share secondary offering. The Carlsbad, California maker of 3-D visualization equipment for minimally invasive surgery had announced in July a headcount and expense reduction effort and plans to seek additional capital, citing slower than anticipated sales growth for its advanced visualization and information integration platform (1"The Gray Sheet" July 19, In Brief)

You may also be interested in...



Vista Medical Technologies

Slower than anticipated sales growth for the firm's advanced visualization and information integration platform used in minimally invasive surgical procedures is cited by the firm in announcing July 14 a headcount reduction and cuts in operating expenses. The firm, which went public via an initial stock offering in 1997 ("The Gray Sheet" March 17, 1997, p. 11), is seeking to raise capital "or to effect a sale or merger of the company"

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel